Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis.
ECP
cGVHD
treatment
Journal
Central-European journal of immunology
ISSN: 1426-3912
Titre abrégé: Cent Eur J Immunol
Pays: Poland
ID NLM: 9702239
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
01
2018
accepted:
10
04
2018
entrez:
23
5
2019
pubmed:
23
5
2019
medline:
23
5
2019
Statut:
ppublish
Résumé
Different forms of graft-versus-host disease (GVHD) remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). The prognosis for steroid-refractory chronic GVHD (cGVHD) remains poor. Our aim was to evaluate extracorporeal photopheresis (ECP) treatment in cGVHD patients with different organ involvement to detect subgroups of patients with the best response. Thirty-four patients who underwent HSCT and developed moderate (n = 7) or severe (n = 27) steroid-refractory or steroid-dependent cGVHD treated with ECP were included in the analysis. A matched cGVHD control patient group untreated with ECP was collected for comparison. Compared to the control group and the stable/progressive disease (SD/PD) patients, individuals with complete/partial remission have higher overall survival and lower transplant-related mortality. Furthermore, patients with complete and partial remission (CR/PR) had significantly higher levels of albumin and platelets after ECP treatment compared to patients with stable or progressive cGVHD (SD/PD). Corticosteroid treatment and other immunosuppressive agents could successfully be tapered in the CR/PR group compared to the SD/PD patients. In this study patients with skin cGVHD are those with the highest rate of CR/PR after ECP treatment. Our results suggest that ECP treatment is safe and effective for patients with predominantly skin, oral and liver cGVHD.
Identifiants
pubmed: 31114441
doi: 10.5114/ceji.2018.75831
pii: 75831
pmc: PMC6526584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
84-91Déclaration de conflit d'intérêts
The authors declare co conflict of interest.
Références
Blood. 2001 Mar 1;97(5):1219-26
pubmed: 11222363
Bone Marrow Transplant. 2001 Jul;28(2):121-9
pubmed: 11509929
Blood. 2001 Nov 15;98(10):2942-7
pubmed: 11698275
Blood. 2003 Aug 15;102(4):1217-23
pubmed: 12714516
Blood. 2005 Jun 1;105(11):4200-6
pubmed: 15701727
Am J Hematol. 2005 Apr;78(4):265-74
pubmed: 15795914
Bone Marrow Transplant. 2005 Jun;35(12):1187-93
pubmed: 15852025
J Immunol. 2005 May 15;174(10):5968-76
pubmed: 15879089
Haematologica. 2005 Aug;90(8):1096-101
pubmed: 16079109
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Blood. 2006 Apr 15;107(8):3074-80
pubmed: 16368882
Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 2):7-12
pubmed: 16399596
Biol Blood Marrow Transplant. 2007 Dec;13(12):1461-8
pubmed: 18022576
Blood. 2008 Oct 1;112(7):2667-74
pubmed: 18621929
Neonatology. 2011;100(1):78-84
pubmed: 21273792
Bone Marrow Transplant. 2012 Jun;47(6):824-30
pubmed: 21927038
Bone Marrow Transplant. 2013 Mar;48(3):439-45
pubmed: 22922407
N Engl J Med. 1975 Apr 17;292(16):832-43
pubmed: 234595
J Clin Oncol. 2013 Apr 20;31(12):1530-8
pubmed: 23478054
Blood. 1990 Jun 15;75(12):2459-64
pubmed: 2350582
N Engl J Med. 1975 Apr 24;292(17):895-902
pubmed: 235092
Transfus Apher Sci. 2014 Jun;50(3):349-57
pubmed: 24780392
Biol Blood Marrow Transplant. 2014 Nov;20(11):1677-86
pubmed: 24867779
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Transfus Apher Sci. 2017 Feb;56(1):17-19
pubmed: 28094112
J Clin Apher. 2018 Dec;33(6):654-660
pubmed: 30394564
N Engl J Med. 1987 Feb 5;316(6):297-303
pubmed: 3543674
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Blood. 1998 Nov 1;92(9):3098-104
pubmed: 9787144